Background: Only around 1% of babies in the UK are breastfed exclusively until six months of age as recommended by the World Health Organisation. One in ten women who have recently given birth in the UK have a long-term illness and they are at increased risk of stopping breastfeeding early. We considered women with autoimmune rheumatic diseases as an exemplar group of long term illnesses, to explore the barriers and enablers to breastfeeding AIM: To understand the experiences of infant feeding among women with autoimmune rheumatic diseases and to identify potential barriers and enablers.
Design: Qualitative visual timeline-facilitated interviews.
Participants And Setting: 128 women with autoimmune rheumatic diseases who were considering pregnancy, pregnant, or had young children took part in an online survey as part of the STAR Family Study. Of these, 13 women who had children were purposefully sampled to be interviewed. Interviews took place in person or on the telephone. Timeline-facilitated interviews were used to focus on lived experiences and topics important to the women, including early parenting. We conducted a focused thematic analysis of women's lived experiences of infant feeding.
Results: Three main themes were identified in relation to breastfeeding: lack of information about medication safety, lack of support in decision-making and maintaining breastfeeding, and maternal guilt.
Conclusions: Women with autoimmune rheumatic diseases found it difficult to access the information they needed about medications to make informed decisions about breastfeeding. They often also felt pressurised into breastfeeding and experienced feelings of guilt if they were unable, or did not wish to breastfeed. Tailored interventions are required that adopt a non-judgmental and person-centred approach to support decision-making in regard to infant feeding, providing women with information that can best enable them to make infant feeding choices.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6750183 | PMC |
http://dx.doi.org/10.1016/j.midw.2019.08.002 | DOI Listing |
Lancet Rheumatol
January 2025
Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U1227), LabEx IGO Brest, France.
Background: Moderate doses of glucocorticoids result in improvements in nearly all patients with polymyalgia rheumatica, but related adverse events are common in older individuals. We aimed to evaluate whether treatment with baricitinib (a Janus kinase 1/2 inhibitor) results in disease control without the use of oral glucocorticoids in people with recent-onset polymyalgia rheumatica.
Methods: We conducted a randomised, double-blind, placebo-controlled, parallel-group trial at six expert centres in France.
Tumor necrosis factor-alpha (TNF-α) inhibitors are commonly used for management of various autoimmune disorders but can rarely cause isolated cutaneous lupus. This report presents two cases of cutaneous lupus erythematosus (LE) in women aged 38 and 61 after adalimumab treatment for psoriasis highlighting the importance of recognizing these paradoxical reactions for timely management.
View Article and Find Full Text PDFInt J Womens Dermatol
March 2025
Department of Dermatology, University of Maryland School of Medicine, Baltimore, Maryland.
Seizure
January 2025
Neurology department, Royal Brisbane and Women's Hospital, Brisbane, Australia.
Objectives: There have been conflicting reports about the frequency of neural autoantibodies in epilepsy cohorts, which is confounded by the lack of clear distinction of epilepsy from acute symptomatic seizures due to encephalitis. The aim of this study was to determine the frequency of neural autoantibodies in a well characterised population of refractory focal epilepsy of known and unknown cause.
Methods: Cases were recruited from epilepsy outpatient clinics at the Princess Alexandra, Mater, Royal Brisbane and Women's and Cairns Base Hospitals from 2021 - 2023.
Prz Menopauzalny
December 2024
Department of Endocrinology, Centre of Postgraduate Medical Education, Warsaw, Poland.
The increase of the incidence of autoimmune diseases and, at the same time, a significant surge in the number of regenerative/anti-aging medicine treatments carried out, raises the need to systematise the current knowledge on the safety of the use of hyaluronic acid fillers in patients with autoimmune diseases and to frame management guidelines for aesthetic doctors. One of the most prevalent autoimmune diseases is chronic lymphocytic thyroiditis, so-called Hashimoto's disease, which affects one in every 5-10 women who visit a regenerative medicine doctor. Women in the perimenopausal and menopausal period, aged 40-54 years, were the single largest target group for aesthetic treatments.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!